President and CEO David A. Cory resigns from the company effective immediately Dr. David Apelian named Interim CEO PALO ALTO, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Eiger BioPharmaceuticals, Inc. (“Eiger” or “the company”) (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals , Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases,
